NPI: 1811428287 · MIAMI, FL 33137 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/27/2017
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP,LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/27/2017 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 1,794 | $327K |
| 2020 | 18,096 | $1.66M |
| 2021 | 18,183 | $699K |
| 2022 | 4,134 | $195K |
| 2023 | 1,121 | $56K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 17,589 | 574 | $1.12M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 14,522 | 809 | $1.11M |
| A4657 | Syringe, with or without needle, each | 1,143 | 560 | $181K |
| J1756 | Injection, iron sucrose, 1 mg | 2,598 | 284 | $148K |
| J1270 | Injection, doxercalciferol, 1 mcg | 2,811 | 145 | $115K |
| 85041 | 914 | 449 | $50K | |
| 85048 | 880 | 427 | $50K | |
| 82728 | 591 | 320 | $44K | |
| 83550 | 586 | 321 | $34K | |
| 83540 | 586 | 321 | $34K | |
| 83970 | 386 | 193 | $24K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 671 | 243 | $11K |
| 82108 | 51 | 36 | $8K |